Synplogen, a synthetic biology startup spun out of Kobe University's Graduate School of Science, Technology and Innovation that provides custom DNA synthesis and Gene Therapy Biofoundry™ services, has ...
BOSTON, Feb. 5, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced it has demonstrated, in collaboration with OpenAI, an AI system that autonomously designed, executed, and learned from ...
Hosted on MSN
Ginkgo Bioworks reaffirms $167M-$187M 2025 revenue target as AI-driven automation and tools expansion accelerate
Earnings Call Insights: Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2025 Jason Kelly, Founder, CEO & Director, emphasized Ginkgo’s mission to "make biology easier to engineer" and outlined three major ...
Ginkgo Bioworks isn't yet profitable, so it's running on a finite amount of cash. Cutting expenses may actually cause the company to lose out on revenue. But if it can survive, Ginkgo could become a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results